A number of corporations will release quarterly earnings results including Sanofi SA (NYSE:SNY) (EPA:SAN), Statoil ASA (NYSE:STO), Siemens AG (NYSE:SI) (FRA:SIE) (ETR:SIE), Zagg Inc (NASDAQ:ZAGG), and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TLV:TEVA) on Thursday, May 2, 2013.
Two analysts covering Sanofi SA (NYSE:SNY) (EPA:SAN) expected the company to report $1.80 earnings per share and $11 billion revenue for the first quarter of the current fiscal year based on data from Yahoo! Finance
On the other hand, the consensus estimate of seven analysts polled by Bloomberg is €8.3 billion revenue. During the fourth quarter of 2012, the company posted €8.5 billion revenue and €0.80 earnings per share.
For fiscal 2013, Sanofi is expected by five analysts to post average earnings per share of €4.68 compared with €4.15 earnings per share in 2012. In terms of revenue, the consensus estimate of 27 analysts is around €35.7 billion, 4.7 percent higher than its €34.9 billion revenue a year ago.
Zacks Investment Research estimated that Statoil ASA (NYSE:STO) will achieve $0.79 earnings per share and $28.18 billion revenue for the first quarter. The company’s previous quarter earnings and revenue were $0.82 per share and $32.26 billion in the same period a year earlier, respectively.
The research firm projected that Statoil will post $2.95 earnings per share and $110.24 billion revenue. Five out of ten analysts covering the stock recommended a hold rating.
Data from Yahoo! Finance indicated that Siemens AG (NYSE:SI) (FRA:SIE) (ETR:SIE) is expected to report an average earnings per share of $1.92 and $26.06 billion revenue compared with its $1.96 EPS and $25.30 billion revenue a year ago.
Analysts expect Siemens to deliver $7.34 earnings per share and $103.59 billion revenue for the year 2013. For next year, the company’s earnings and revenue are projected to increase to $9.74 per share and $106.66 billion, respectively.
Zagg Inc (NASDAQ:ZAGG) is expected by post $0.25 earnings per share and $66.5 million revenue based on data from Bloomberg. During the previous quarter, its earnings and revenue were $0.35 per share and $87.5 million, respectively.
Analysts anticipated that the company will achieve $1.17 earnings per share and $316 million revenue for the entire 2013. A year earlier, the company reported $1.01 earnings per share and $264 million revenue. The current full-year revenue estimate is 47.6 percent higher than the its financial performance in 2012.
Meanwhile, Zacks Investment Research estimated that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TLV:TEVA) anticipated that it will report lower earnings of $1.10 per share for the current quarter compared with its $1.47 earnings per share a year ago. Its revenue is projected to decrease by 4.9 percent year-over-year to $4.85 billion. In the same quarter in 2012, the company achieved $5.1 billion revenue.
For fiscal 2013, Teva Pharmaceutical Industries is expected to deliver $5.08 earnings per share and $20.2 billion revenue.
